





Figure 1. C4-V3 Th-CTL Peptides Induce HLA B7 Reactive CD8+ CTL in Normal HIV-1 Seronegative Humans. Panels A a C show specific lysis from in vivo immunization and in vito restimulation against each of the V3 B7 CTL epitope variants. BLCL-lymphoblastoid cell line (BCLC) no peptide coating control. C4=C4 Th determinant peptide on BCLC, V3MN, V3RF, V3EV91, av V3CanOA are the B7 CTL epitope variants peptide coated on BCLC. Data show patient in Panel A responded to 1 of 4 B7 CTL epitope variants (the HIV EV91 variant) while the patient in Panel C responded to 3 of 4 B7 epitope variants (HIVMN, EV91 and CanO). Panels B and D show 2 HLA B7 negative individuals that made no CTL response to the B7-restricted CTL peptide immunogen after both in in vivo immunization and in vitto restimulation.

H. H. Garrell, R. H. H. Sterner, R. H. H. Sterner, R. L. M. Blong, H. M. Barrell, H. B. Barrell, H. B. Barrell, H. B. Barrell, H. B. Barrell, H. Barre